Utama › Kanser Tiroid › Texas
Kajian klinikal Kanser Tiroid di Texas
15 kajian untuk Kanser Tiroid sedang mencari peserta di lokasi di Texas.
Bandar di Texas
Teks kajian rasmi (Bahasa Inggeris)
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- The Don and Sybil Harrington Cancer Center, Amarillo
- UT MD Anderson Cancer Center, Houston
- Audie L Murphy VA Hospital, San Antonio
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 40 hingga 75 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT05334069DESTINY-PANTUMOUR04
- Research Site, Dallas
Mengambil pesertaKajian pemerhatian
Umur 18 hingga 130 · Semua jantina · Dikemas kini 25 Sep 2026 · NCT07124000Global Real World Data in Patients With Advanced Thyroid Cancer on Standard of Care and Specialized Interventions- Registry of Oncologic Outcomes With Testing and Treatment.
- MD Anderson Cancer Center, Houston
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 18 Sep 2026 · NCT06507878Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- MD Anderson Cancer Center, Houston
- START San Antonio, San Antonio
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 16 Sep 2026 · NCT05786924Nanosecond Pulsed Field Ablation in the Management of T1N0M0 Papillary Thyroid Carcinoma
- The University of Texas M. D. Anderson Cancer Center, Houston
Mengambil peserta
Umur 18 ke atas · Semua jantina · Dikemas kini 11 Sep 2026 · NCT07218315Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery
- MD Anderson Cancer Center, Houston
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 4 Sep 2026 · NCT06959511Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)
- MD Anderson Cancer Center, Houston
Mengambil pesertaFasa 2
Umur 2 hingga 25 · Semua jantina · Dikemas kini 24 Jul 2026 · NCT06458036A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
- UT Southwestern Medical Center, Dallas
- MD Anderson Cancer Center, Houston
Mengambil pesertaFasa 1/2
Umur 12 ke atas · Semua jantina · Dikemas kini 27 Mei 2026 · NCT03093116An Investigational Scan (hpMRI) for Monitoring Treatment Response in Patients With Thyroid Cancer and Other Malignancies of the Head and Neck Undergoing Radiation Therapy and/or Systemic Therapy
- M D Anderson Cancer Center, Houston
Mengambil pesertaFasa 1Sukarelawan sihat dialu-alukan
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Mei 2026 · NCT04589624Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
- MD Anderson Cancer Center, Houston
- NEXT Oncology, San Antonio
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 6 Mei 2026 · NCT06239194Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial
- M D Anderson Cancer Center, Houston
Mengambil peserta
Umur 18 ke atas · Semua jantina · Dikemas kini 15 Apr 2026 · NCT04693377cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Elligo Health Research, Inc., Austin
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 40 ke atas · Semua jantina · Dikemas kini 20 Jan 2026 · NCT05366881Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer
- MD Anderson Cancer Center, Houston
Mengambil pesertaFasa 2
Umur 2 hingga 99 · Semua jantina · Dikemas kini 14 Nov 2025 · NCT05783323Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions
- University of Texas Health Science Center, San Antonio
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Semua umur · Semua jantina · Dikemas kini 15 Okt 2025 · NCT03160274Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
- MD Anderson Cancer Center, Houston
Mengambil pesertaFasa 2
Umur 12 ke atas · Semua jantina · Dikemas kini 12 Dis 2024 · NCT05668962Daripada ClinicalTrials.gov, data diperoleh pada 4 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.